Heartflow (NASDAQ:HTFL) Upgraded at Freedom Capital

Freedom Capital upgraded shares of Heartflow (NASDAQ:HTFL) to a strong-buy rating in a research report released on Tuesday,Zacks.com reports.

HTFL has been the subject of several other research reports. Weiss Ratings raised Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, June 12th. JPMorgan Chase & Co. decreased their target price on Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday, March 19th. Wells Fargo & Company raised their price target on Heartflow from $35.00 to $37.00 and gave the company an “overweight” rating in a report on Friday, May 15th. William Blair assumed coverage on Heartflow in a research report on Monday, May 4th. They set an “outperform” rating for the company. Finally, Canaccord Genuity Group cut their price objective on Heartflow from $43.00 to $37.00 and set a “buy” rating for the company in a report on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.00.

Heartflow Trading Down 8.9%

Heartflow stock opened at $27.97 on Tuesday. The firm’s 50 day simple moving average is $30.66 and its 200 day simple moving average is $28.69. The firm has a market capitalization of $2.41 billion and a PE ratio of -8.99. Heartflow has a 1-year low of $20.13 and a 1-year high of $41.22.

Heartflow (NASDAQ:HTFL) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.08. The firm had revenue of $52.59 million during the quarter. The firm’s quarterly revenue was up 41.3% compared to the same quarter last year. Research analysts forecast that Heartflow will post -0.82 earnings per share for the current year.

Insider Activity at Heartflow

In related news, CEO John C.M. Farquhar sold 38,900 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $35.00, for a total value of $1,361,500.00. Following the completion of the sale, the chief executive officer owned 457,935 shares in the company, valued at $16,027,725. The trade was a 7.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Bain Capital Life Sciences Inv sold 948,757 shares of the company’s stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $29.23, for a total value of $27,732,167.11. Following the completion of the sale, the insider directly owned 8,448,158 shares of the company’s stock, valued at approximately $246,939,658.34. This represents a 10.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 2,115,805 shares of company stock valued at $62,422,505. Corporate insiders own 7.70% of the company’s stock.

Institutional Investors Weigh In On Heartflow

Institutional investors have recently made changes to their positions in the business. Essential Partners LLC purchased a new position in Heartflow in the 1st quarter worth $57,000. Bank of America Corp DE boosted its position in Heartflow by 28.8% during the first quarter. Bank of America Corp DE now owns 111,702 shares of the company’s stock valued at $2,718,000 after buying an additional 24,964 shares during the period. Janus Henderson Group PLC boosted its position in Heartflow by 152.0% during the first quarter. Janus Henderson Group PLC now owns 2,180,976 shares of the company’s stock valued at $53,063,000 after buying an additional 1,315,416 shares during the period. California State Teachers Retirement System grew its stake in shares of Heartflow by 41.9% during the first quarter. California State Teachers Retirement System now owns 29,371 shares of the company’s stock valued at $715,000 after buying an additional 8,678 shares during the last quarter. Finally, Royal Bank of Canada lifted its stake in shares of Heartflow by 24.4% in the 1st quarter. Royal Bank of Canada now owns 137,421 shares of the company’s stock valued at $3,343,000 after acquiring an additional 26,912 shares during the last quarter.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.